Scarica l'app Stockscreener
0.867
2.30%
0.0195
Dopo l'orario di chiusura:
.88
0.013
+1.50%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BTAI Giù?
Forum
Previsione
Precedente Chiudi:
$0.8475
Aprire:
$0.8475
Volume 24 ore:
242.78K
Relative Volume:
0.27
Capitalizzazione di mercato:
$26.77M
Reddito:
$680.00K
Utile/perdita netta:
$-75.33M
Rapporto P/E:
-0.1401
EPS:
-6.1898
Flusso di cassa netto:
$-57.38M
1 W Prestazione:
-1.77%
1M Prestazione:
-33.82%
6M Prestazione:
-51.02%
1 anno Prestazione:
-52.10%
Intervallo 1D:
$0.8401
$0.8784
Intervallo di 1 settimana:
$0.83
$0.9235
Portata 52W:
$0.7365
$8.08
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Nome
Bioxcel Therapeutics Inc
Settore
Telefono
203-643-8060
Indirizzo
555 LONG WHARF DRIVE, NEW HAVEN, CT
Compare BTAI vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
0.867 | 26.17M | 680.00K | -75.33M | -57.38M | -6.1898 |
TAK
Takeda Pharmaceutical Co Adr
|
17.44 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.94 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.08 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.92 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
527.94 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-17 | Iniziato | Rodman & Renshaw | Buy |
| 2024-02-21 | Downgrade | UBS | Buy → Neutral |
| 2023-08-15 | Downgrade | Mizuho | Buy → Neutral |
| 2023-07-17 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-03-10 | Downgrade | Jefferies | Buy → Hold |
| 2022-12-01 | Aggiornamento | Goldman | Sell → Neutral |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-04-06 | Reiterato | BofA Securities | Buy |
| 2021-11-15 | Downgrade | Goldman | Neutral → Sell |
| 2021-04-09 | Iniziato | Berenberg | Buy |
| 2021-02-01 | Iniziato | UBS | Buy |
| 2020-10-30 | Iniziato | Goldman | Buy |
| 2020-09-02 | Iniziato | Jefferies | Buy |
| 2020-08-17 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-04 | Iniziato | Guggenheim | Buy |
| 2020-04-01 | Iniziato | BofA/Merrill | Buy |
| 2020-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
Mostra tutto
Bioxcel Therapeutics Inc Borsa (BTAI) Ultime notizie
BioXcel Therapeutics Inc (BTAI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BTAI|BioXcel Therapeutics Inc|Price:0.848|Chg%:-0.023 - TradingKey
BioXcel Therapeutics Inc (BTAI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BioXcel Therapeutics Inc (BTAI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TradingKey - TradingKey
BioXcel Therapeutics Inc|Price:0.848|Chg%:-0.023 - TradingKey
BioXcel Therapeutics Inc (BTAI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
[Latest] Global AI in Drug Repurposing Market Size/Share Worth USD 10.56 Billion by 2035 at a 23.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
BioXcel Therapeutics Q1 2026 Earnings: EPS Beats Estimates by 35.72% Amid Continued Cost ManagementShare Dilution Risk - dars.gov.et
BTAI News | BIOXCEL THERAPEUTICS INC (NASDAQ:BTAI) - ChartMill
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
BioXcel Therapeutics (BTAI) Rallies 7.9% as Biotech Stock Tests Key Resistance at $0.92ALMA Signal - dars.gov.et
BioXcel Therapeutics (BTAI) Investor update Summary - Quartr
BioXcel Therapeutics (BTAI) Q1 2026 earnings summary - Quartr
BioXcel Therapeutics (BTAI) Registration Filing Summary - Quartr
BioXcel Therapeutics (BTAI) Q2 2024 earnings summary - Quartr
BioXcel Therapeutics (BTAI) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary - Quartr
BioXcel Therapeutics (BTAI) Q4 2025 earnings summary - Quartr
BTAI Q1 2026 Earnings: Narrowing Losses as EPS Surpasses Estimates Amid Pipeline ProgressROE Trend Analysis - Bölüm Sonu Canavarı
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
BioXcel (NASDAQ: BTAI) eases liquidity covenant and defers $9M loan payment - Stock Titan
BioXcel Therapeutics Amends Credit Agreement, Tightens Liquidity - TipRanks
BioXcel Therapeutics (BTAI) Holds Above $1.31 Support Amid Modest UptickFundamentals - dars.gov.et
BTAIBioXcel Therapeutics Inc Options - Finviz
Price to sales forward of BioXcel Therapeutics, Inc. – NASDAQ:BTAI - TradingView
BTAI Stock Gained 5% TodayWhat's The Latest On Its Opioid Withdrawal Treatment? - Stocktwits
Price to sales forward of BioXcel Therapeutics, Inc. – MUN:BX20 - TradingView
BioXcel Therapeutics, Inc.(NasdaqCM: BTAI) added to Russell 3000E Growth Benchmark - marketscreener.com
BioXcel Therapeutics, Inc.(NasdaqCM: BTAI) added to Russell Microcap Index - marketscreener.com
BioXcel Therapeutics, Inc.(NasdaqCM: BTAI) added to Russell 3000E Index - marketscreener.com
BioXcel Therapeutics, Inc.(NasdaqCM:BTAI) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Price to book forward of BioXcel Therapeutics, Inc. – NASDAQ:BTAI - TradingView
Price to earnings forward of BioXcel Therapeutics, Inc. – NASDAQ:BTAI - TradingView
Enterprise value to revenue forward of BioXcel Therapeutics, Inc. – NASDAQ:BTAI - TradingView
Enterprise value to EBITDA forward of BioXcel Therapeutics, Inc. – NASDAQ:BTAI - TradingView
BioXcel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Yocca Frank - Moomoo
BioXcel Therapeutics, Inc. Actuals & Estimates (FWB:BX20) - TradingView
BTAI Should I Buy - Intellectia AI
BioXcel Therapeutics, Inc. Actuals & Estimates (NASDAQ:BTAI) - TradingView
BioXcel Therapeutics, Inc. Actuals & Estimates (LSX:A40YSR) - TradingView
BTAI Forecast — Price Target — Prediction for 2027 - TradingView
BioXcel Therapeutics Inc. (BTAI) Q1 2026 Earnings: Surprise EPS Beat Drives Stock RallyEarnings Per Share - dars.gov.et
SGMOQ Stock Price and Chart — OTC:SGMOQ - TradingView
BioXcel Therapeutics Q1 2026 Earnings: EPS Beat Driven by Cost Controls Despite No RevenuePost-Announcement Reaction - Město Břeclav
BTAI Q1 2026 Earnings: EPS Beat Amid No Revenue; Stock Edges UpEarnings Growth Analysis - dars.gov.et
BioXcel Therapeutics (NASDAQ: BTAI) officer converts RSUs into Common Stock - Stock Titan
BioXcel (BTAI) CEO exercises 219 RSUs and reports major indirect stakes - Stock Titan
BioXcel Therapeutics (BTAI) CSO converts 35 RSUs, now holds 26,210 shares - Stock Titan
BioXcel (BTAI) CFO gains 35 shares as 212 RSUs remain - Stock Titan
BioXcel Therapeutics Inc (BTAI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BioXcel Therapeutics Inc (BTAI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bioxcel Therapeutics Inc Azioni (BTAI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.30%
2.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):